J Cancer
2011; 2:329-330.
doi:10.7150/jca.2.329 This volumeCite
Short Report
A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients
Vincenzo Russo1, Francesca Lunghi2, Raffaella Fontana1, Marco Bregni3 ✉
1. Cancer Gene Therapy Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy; 2. Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy; 3. Strategic Program in Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy.
✉ Corresponding author: Marco Bregni, M.D., Department of Hematology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy. Phone 39-02-26434409 Fax 39-02-26434760 e-mail marco.bregniit
Citation:
Russo V, Lunghi F, Fontana R, Bregni M. A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients. J Cancer 2011; 2:329-330. doi:10.7150/jca.2.329. https://www.jcancer.org/v02p0329.htm
In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3+ melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were assessed by in vitro assay and delayed-type hypersensitivity skin testing.
Keywords: MAGE-A3, Melanoma, Immunotherapy
Citation styles
APA
Russo, V., Lunghi, F., Fontana, R., Bregni, M. (2011). A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients. Journal of Cancer, 2, 329-330. https://doi.org/10.7150/jca.2.329.
ACS
Russo, V.; Lunghi, F.; Fontana, R.; Bregni, M. A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients. J. Cancer 2011, 2, 329-330. DOI: 10.7150/jca.2.329.
NLM
Russo V, Lunghi F, Fontana R, Bregni M. A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients. J Cancer 2011; 2:329-330. doi:10.7150/jca.2.329. https://www.jcancer.org/v02p0329.htm
CSE
Russo V, Lunghi F, Fontana R, Bregni M. 2011. A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients. J Cancer. 2:329-330.